Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 26, Issue 21, pp. 5557-5566
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 15, 2020
- Revision received May 8, 2020
- Accepted June 19, 2020
- Published first June 23, 2020.
Article Versions
- Previous version (June 23, 2020 - 06:24).
- Previous version (September 17, 2020 - 05:56).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- 1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
- 3Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
- 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- ↵*Corresponding Authors:
Jean J. Zhao, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215. Phone: 617-632-2932; Fax: 617-632-4770; E-mail: jean_zhao{at}dfci.harvard.edu; and Johann S. Bergholz, johann_bergholz{at}dfci.harvard.edu
↵#J.S. Bergholz and Q. Wang contributed equally to this article.
November 2020
Volume 26, Issue 21
Volume 26, Issue 21
Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
Jump to section
- Article
- Abstract
- Introduction
- Immune Evasion by Cancer Cells
- Oncogenic Signaling Pathways Shape the Tumor Immune Microenvironment
- Integrating Small-molecule Targeted Therapy and Immunotherapy to Improve Therapeutic Outcomes
- Future Prospects
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement